Company Snapshot: BGEN  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Biogen to Provide Mid-Quarter Financial Update

   BIOGEN LOGO
Biogen Logo. (PRNewsFoto)[KC]
CAMBRIDGE, MA USA
           Conference Call -- Friday, June 7, 2002 at 8:30 AM (EDT)

    CAMBRIDGE, Mass., June 6 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) will provide a mid-quarter financial update,
Friday, June 7, 2002.  A conference call is scheduled for tomorrow at 8:30 am
(EDT).
    (Photo:  http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )

    To access the conference call, please dial:
     Domestic:           877-650-1145
     International:      706-643-1326

    To access the replay of the conference call, please dial:
     Domestic:           800-642-1687
     International:      706-645-9291
     Passcode:           4449916

    The replay will be available for one week.
    A live webcast is also available by logging on to Biogen's homepage,
http://www.biogen.com.

    About Biogen
    Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biopharmaceutical company principally engaged in discovering and developing
drugs for human healthcare through genetic engineering.  Headquartered in
Cambridge, MA, the Company's revenues are generated from U.S. and worldwide
sales of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of
multiple sclerosis, and from the worldwide sales by licensees of a number of
products.  Biogen's research and development activities are focused on novel
products to treat inflammatory and autoimmune diseases, neurological diseases,
cancer, fibrosis and congestive heart failure.  The Company maintains active
clinical research programs in protein therapeutics, small molecules, genomics
and gene therapy.  For copies of press releases and additional information
about the Company, please consult Biogen's Homepage on the World Wide Web at
http://www.biogen.com.

    Contact:
     Rob Jacobson
     Investor Relations Specialist
     Biogen, Inc.
     617/679-3710
     rob_jacobson@biogen.com



SOURCE Biogen, Inc.




Back to Topback to top

Related links:
  • http://www.biogen.com
    Company News On-Call:
  • http://www.prnewswire.com/comp/101550.html
    Photo Notes:
    NewsCom: 
    http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
    AP Archive: http://photoarchive.ap.org
    PRN Photo Desk, 888-776-6555 or 212-782-2840
    CONTACT:
    Rob Jacobson, Investor Relations Specialist
    of Biogen, Inc., +1-617-679-3710, rob_jacobson@biogen.com